

## News Release

January 22, 2026  
Maruho Co., Ltd.

### **Maruho Announces Out-Licensing Agreement for Hyperhidrosis Treatment (Topical Anticholinergic Agent) in Taiwan**

Osaka (Japan), January 22, 2026 – Maruho Co., Ltd. ("Maruho"; Head Office: Osaka, Japan, President and CEO, Atsushi Sugita) announced that it has entered into a licensing agreement with Orient EuroPharma Co., Ltd. ("OEP"; Head Office: Taipei, Taiwan, Chairman, Peter Tsai) to out-license the development and marketing rights in Taiwan for a hyperhidrosis treatment agent for primary axillary hyperhidrosis (JAN: Glycopyrronium tosilate hydrate\*<sup>1</sup>; hereinafter referred to as "the product") that Maruho manufactures and markets in Japan.

Based on this agreement, Maruho will grant OEP exclusive rights to develop and market the product. OEP will pay Maruho an upfront payment and milestone payments based on development and regulatory progress.

The product reduces sweat production by blocking the activation of acetylcholine receptors in sweat glands. In Japan, it has been marketed since May 2022 under the product name "Rapifort® Wipes 2.5%" as a treatment for primary axillary hyperhidrosis.

Maruho, with its new overseas business strategy the "Asia Dermatology Hub Concept", is promoting business development in Asian countries and regions\*<sup>2</sup>. This agreement is an initiative aimed at realizing business expansion in Asia and addresses the unmet needs of patients who have limited treatment options for hyperhidrosis. By providing the product in collaboration with OEP, we aim to bring smiles to the faces of patients suffering from hyperhidrosis in Taiwan.

\*1: In September 2023, Maruho signed a licensing agreement with Journey Medical Corporation for exclusive rights to the product in South Korea, Taiwan, Hong Kong, Macau, and ASEAN countries.

\*2: Since October 2023, as part of its Fifth Medium-Term Plan, Maruho has been focusing on "Taking a new step in global expansion" as one of its priority themes.

#### **Note**

The information contained in this news release in regard to pharmaceutical and developmental products is not intended for the purpose of promotion, advertising or medical advice.



#### **References**

Maruho enters a License Agreement with Dermira for Hyperhidrosis treatment agent DRM04 (September 2016)

<https://www.maruho.co.jp/english/information/2016092102.html>

Maruho Receives Manufacturing and Marketing Approval for Primary Axillary Hyperhidrosis Treatment "Rapifort Wipes 2.5%" in Japan (January 2022)

<https://www.maruho.co.jp/english/information/20220120.html>

Maruho Launches Primary Axillary Hyperhidrosis Treatment "Rapifort Wipes 2.5%" in Japan (May 2022)

<https://www.maruho.co.jp/english/information/20220523.html>

Maruho and Journey Medical Corporation Enter into an Exclusive License Agreement for a Hyperhidrosis Treatment (Topical Anticholinergic Agent) in Asia (September 2023)

<https://www.maruho.co.jp/english/information/20230907.html>

#### **About Orient EuroPharma Co., Ltd.**

Orient EuroPharma Co., Ltd. (OEP), established in 1982, has grown into a leading multinational pharmaceutical company headquartered in Taiwan. Listed on the Taipei Exchange (TPEX) since 2003. (4120.TW), OEP has built a strong presence across Southeast Asia, with extensive sales network in the region. OEP's diversified portfolio spans prescription pharmaceuticals, oncology treatments, cosmeceuticals, and infant-to-adult nutrition and health products. The company also operates a dedicated subsidiary for innovative drug development and manufacturing. With integrated capabilities in pharmaceutical R&D, clinical trials, manufacturing, and regional marketing, OEP continues to advance healthcare solutions throughout Taiwan and the broader Asia-Pacific region.

For more information, please visit <https://www.oepgroup.com/en-global>

#### **About Maruho**

Maruho Co., Ltd. has its head office in Osaka and leads Japan in research and development, manufacturing and commercialization of dermatological products. Founded in 1915, Maruho has 1,632 employees (as of the end of September 2025), and net sales were approximately 78.92 billion yen in its fiscal year ended September 30, 2025. With the mission "More smiles, brighter life for you.", Maruho aims to help realize a society where everyone can live with a smile.

For more information, please visit <https://www.maruho.co.jp/english/>

#### **Contact Information:**

Maruho Co., Ltd.

Public Relations Group, Corporate Planning Dept.

Tel: +81-(0)6-6371-8831

Email: [kouhou@mii.maruho.co.jp](mailto:kouhou@mii.maruho.co.jp)